In 2017, 64 years after the publication of the structure of DNA, the first gene therapy became clinically available in the United States, a treatment for a sight-robbing eye disease. A year later, chimeric antigen receptor (CAR)-T cell therapy became available. These immune system cells are genetically modified to target therapy-resistant cancers. A handful more cell and gene therapies for a broad range of diseases have been approved around the world, each of them offering treatment for diseases that may have previously been considered undruggable. Many more drug candidates are barreling down the pipeline, and cell and gene therapies have only just begun to demonstrate their capabilities.

Both gene and cell therapies, in which clinicians fix a dysfunctional gene in and introduce disease-fighting cells to a patient, respectively, can be a challenge to manufacture. The challenges include scaling up cell production, harvesting and washing cells without a loss of viability, ensuring the longevity and selectivity of CAR-T cells, and, in the end, effectively delivering a therapy to a patient.

Flow cytometry has become a key tool in the development and manufacture of gene and cell therapies. The approach can rapidly identify cell defects, assess cell function and viability, monitor the cell cycle, and confirm if a therapeutic genetic modification is functioning in a cell. In this webinar, researchers at the front lines of gene and cell therapies discuss recent advances in the field and the technologies that are making the next generation of these treatments a reality.

During this webinar, viewers will:

• Learn about the latest techniques and strategies used in the development and manufacture of gene and cell therapies
• Hear about current applications for flow cytometry in cell and gene therapy
• Explore flow cytometry’s benefits and limitations in cell and gene therapy, as well as look at what new applications are on the horizon.

If you’ve already registered, please click here to login to the webinar.